Prevention of recurrent autoimmune diabetes in BB rats by anti-asialo-GM1 antibody. 1988

J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia.

BB rats exhibit a syndrome of spontaneous diabetes that has clinical and pathological characteristics analogous to those found in human insulin-dependent diabetes mellitus (IDDM). Islet tissue transplanted into spontaneously diabetic BB rats is uniformly destroyed by a recurrence of the autoimmune response that destroyed the diabetic subject's native islets. To examine recurrent autoimmune destruction of transplanted islets, it is necessary to exclude islet damage that might result from allograft rejection. We utilized neonatal tolerance induction to prevent rejection of Wistar-Furth (WF) (RT1u) islet allografts by spontaneously diabetic BB recipients. We determined that islet-recipient treatment with anti-asialo-GM1 (anti-AGM1) antibody prevents recurrent autoimmune diabetes that would otherwise destroy transplanted WF islet grafts. Anti-AGM1 therapy significantly decreased peripheral blood natural killer (NK) cell activity. These data suggest a role for NK cells in the pathogenesis of recurrent diabetes in neonatally tolerant BB rats.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D011913 Rats, Inbred BB A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT). BB Wistar Rats,Bio-Breeding Inbred Rats,Rats, BB,BB Rat,BB Rat, Inbred,BB Rats,BB Rats, Inbred,Bio Breeding Inbred Rats,Bio-Breeding Inbred Rat,Inbred BB Rat,Inbred BB Rats,Inbred Rat, Bio-Breeding,Inbred Rats, Bio-Breeding,Rat, BB,Rat, Bio-Breeding Inbred,Rat, Inbred BB,Rats, BB Wistar,Rats, Bio-Breeding Inbred,Wistar Rats, BB
D011920 Rats, Inbred WF An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Wistar Furth,Rats, Wistar Furth,Rats, WF,Inbred WF Rat,Inbred WF Rats,Rat, Inbred WF,Rat, WF,WF Rat,WF Rat, Inbred,WF Rats,WF Rats, Inbred,Wistar Furth Rats
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D005677 G(M1) Ganglioside A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis. GM1 Ganglioside,Monosialosyl Tetraglycosyl Ceramide,GM1a Monosialoganglioside,Ceramide, Monosialosyl Tetraglycosyl,Ganglioside, GM1,Monosialoganglioside, GM1a,Tetraglycosyl Ceramide, Monosialosyl
D006028 Glycosphingolipids Lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide (CERAMIDES). They are subdivided into NEUTRAL GLYCOSPHINGOLIPIDS comprising monoglycosyl- and oligoglycosylsphingoids and monoglycosyl- and oligoglycosylceramides; and ACIDIC GLYCOSPHINGOLIPIDS which comprises sialosylglycosylsphingolipids (GANGLIOSIDES); SULFOGLYCOSPHINGOLIPIDS (formerly known as sulfatides), glycuronoglycosphingolipids, and phospho- and phosphonoglycosphingolipids. (From IUPAC's webpage) Asialoganglioside,Asialogangliosides,Glycosphingolipid,Sphingoglycolipid,Sphingoglycolipids

Related Publications

J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
May 1991, Diabetes research (Edinburgh, Scotland),
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
January 1997, Endocrinology,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
December 2003, Journal of clinical neuromuscular disease,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
May 1981, Nature,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
January 1992, Immunopharmacology and immunotoxicology,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
January 1986, Acta pathologica japonica,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
April 1991, Diabetes research (Edinburgh, Scotland),
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
June 1987, Japanese journal of cancer research : Gann,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
May 1992, Transplantation,
J D Jacobson, and J F Markmann, and K L Brayman, and C F Barker, and A Naji
January 1990, Natural immunity and cell growth regulation,
Copied contents to your clipboard!